Viewing Study NCT00117039



Ignite Creation Date: 2024-05-05 @ 11:42 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00117039
Status: COMPLETED
Last Update Posted: 2008-10-15
First Post: 2005-06-30

Brief Title: A Study to Evaluate the Effectiveness of Aranesp for Cancer Patients With Anemia
Sponsor: Amgen
Organization: Amgen

Study Overview

Official Title: SYNCHRONICITY A Study to Evaluate the Effectiveness of Aranesp at 300 Mcg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy
Status: COMPLETED
Status Verified Date: 2008-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this trial is to assess the effectiveness of Aranesp administered at 300 mcg every 3 weeks q3w in achieving therapeutic objectives of anemia treatment achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network NCCN guidelines
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None